# Editas Medicine, Inc.: overview EDIT · Nasdaq · CIK 1650664 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/edit.md) · [Financials](/companies/edit/financials.md) · [Filings](/companies/edit/filings.md) · [Insiders](/companies/edit/insiders.md) Latest reported revenue: [$11.9m](/filings/0001650664-26-000083.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001650664-26-000083). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001650664-25-000156.md) | [30.6 d](/filings/0001650664-26-000017.md) | [4.7](/filings/0001650664-26-000045.md) | [3.6](/filings/0001650664-26-000083.md) | [7.5](/filings/0001650664-25-000156.md) | [24.7 d](/filings/0001650664-26-000017.md) | [2.8](/filings/0001650664-26-000045.md) | [11.9](/filings/0001650664-26-000083.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(107649.2%)](/filings/0001650664-25-000156.md) | [(152.2%) d](/filings/0001650664-26-000017.md) | [(1635.1%)](/filings/0001650664-26-000045.md) | [(1440.6%)](/filings/0001650664-26-000083.md) | [(325.4%)](/filings/0001650664-25-000156.md) | [(31.3%) d](/filings/0001650664-26-000017.md) | [(883.2%)](/filings/0001650664-26-000045.md) | [(156.0%)](/filings/0001650664-26-000083.md) | | Net margin | % | [(101870.5%)](/filings/0001650664-25-000156.md) | [(148.3%) d](/filings/0001650664-26-000017.md) | [(1633.5%)](/filings/0001650664-26-000083.md) | [(1487.8%)](/filings/0001650664-26-000083.md) | [(333.0%)](/filings/0001650664-25-000156.md) | [(22.7%) d](/filings/0001650664-26-000017.md) | [(882.4%)](/filings/0001650664-26-000083.md) | [(153.3%)](/filings/0001650664-26-000083.md) | | Diluted EPS | $ per share | [(0.75)](/filings/0001650664-25-000156.md) | not reported | [(0.92)](/filings/0001650664-26-000045.md) | [(0.63)](/filings/0001650664-26-000083.md) | [(0.28)](/filings/0001650664-25-000156.md) | not reported | [(0.26)](/filings/0001650664-26-000045.md) | [(0.15)](/filings/0001650664-26-000083.md) | | Free cash flow | $m | [(55.5) d](/filings/0001650664-25-000156.md) | [(51.3) d](/filings/0001650664-26-000017.md) | [(47.9)](/filings/0001650664-26-000045.md) | [(50.2) d](/filings/0001650664-26-000083.md) | [(31.3) d](/filings/0001650664-25-000156.md) | [(36.4) d](/filings/0001650664-26-000017.md) | [(23.2)](/filings/0001650664-26-000045.md) | [(29.7) d](/filings/0001650664-26-000083.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [25.5](/filings/0001650664-24-000008.md) | [19.7](/filings/0001650664-25-000022.md) | [78.1](/filings/0001650664-25-000022.md) | [32.3](/filings/0001650664-26-000017.md) | [40.5](/filings/0001650664-26-000017.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(756.1%)](/filings/0001650664-24-000008.md) | [(1146.3%)](/filings/0001650664-25-000022.md) | [(216.6%)](/filings/0001650664-25-000022.md) | [(777.2%)](/filings/0001650664-26-000017.md) | [(394.9%)](/filings/0001650664-26-000017.md) | | Net margin | % | [(753.6%)](/filings/0001650664-24-000008.md) | [(1118.3%)](/filings/0001650664-25-000022.md) | [(196.1%)](/filings/0001650664-25-000022.md) | [(733.7%)](/filings/0001650664-26-000017.md) | [(395.0%)](/filings/0001650664-26-000017.md) | | Diluted EPS | $ per share | [(2.85)](/filings/0001650664-24-000008.md) | [(3.21)](/filings/0001650664-25-000022.md) | [(2.02)](/filings/0001650664-25-000022.md) | [(2.88)](/filings/0001650664-26-000017.md) | [(1.80)](/filings/0001650664-26-000017.md) | | Free cash flow | $m | [(172)](/filings/0001650664-24-000008.md) | [(181)](/filings/0001650664-25-000022.md) | [(137)](/filings/0001650664-25-000022.md) | [(219)](/filings/0001650664-26-000017.md) | [(166)](/filings/0001650664-26-000017.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/edit/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $36.0m | 11,111,111 | | New +11,111,111 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $34.3m | 10,589,990 | | Added +1,326,678 | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $28.8m | 8,889,000 | | New +8,889,000 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $28.8m | 8,889,000 | | New +8,889,000 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $28.8m | 8,889,000 | | New +8,889,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $19.9m | 6,141,336 | | Added +1,936,967 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $18.1m | 5,586,625 | | New +5,586,625 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $12.5m | 3,861,930 | | Added +1,934,933 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $11.7m | 3,598,339 | | Added +449,769 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $11.5m | 3,555,497 | | New +3,555,497 | ## Recent filings [All 716 filings](/companies/edit/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 07:04 ET | [8-K](/filings/0001650664-26-000093.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001650664-26-000093 | | 2026-08-05 | 16:05 ET | [10-Q](/filings/0001650664-26-000083.md) | Quarterly report, period 2026-06-30 | 0001650664-26-000083 | | 2026-08-05 | 16:03 ET | [8-K](/filings/0001650664-26-000082.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001650664-26-000082 | | 2026-06-18 | 16:28 ET | [8-K](/filings/0001650664-26-000063.md) | 5.07 Shareholder vote results | 0001650664-26-000063 | | 2026-05-26 | 16:42 ET | [8-K](/filings/0001104659-26-066317.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-066317 | | 2026-05-26 | 08:07 ET | [8-K](/filings/0001104659-26-066021.md) | 8.01 Other events | 0001104659-26-066021 | | 2026-05-26 | 06:09 ET | [8-K](/filings/0001104659-26-065908.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-065908 | | 2026-05-14 | 06:16 ET | [8-K](/filings/0001650664-26-000049.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001650664-26-000049 | | 2026-05-05 | 16:16 ET | [10-Q](/filings/0001650664-26-000045.md) | Quarterly report, period 2026-03-31 | 0001650664-26-000045 | | 2026-05-05 | 07:03 ET | [8-K](/filings/0001650664-26-000043.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001650664-26-000043 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001650664-26-000017.md), filed Mar 9, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7b78e748-e07f-4d2e-89ff-e85a65eb6f72) ## About the filer - CIK: 1650664 - Tickers: EDIT - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:28 ET. No prices; not investment advice.